Results 221 to 230 of about 3,627,754 (377)

Cancer incidence and the influence of immunosuppressive agents in Korean patients with systemic lupus erythematosus: a retrospective cohort study. [PDF]

Arthritis Res Ther
Cho SK, Han JY, Jeon Y, You SH, Jung SY, Jang EJ, Sung YK.   +6 more
europepmc   +1 more source

Vaccines: Considerations for pediatric dermatology patients on immunosuppressive agents. [PDF]

Pediatr Dermatol, 2021
Munshi MA, Noe MH, Chiu YE, Streicher JL.   +3 more
europepmc   +1 more source

Immunosuppressive agents for treating IgA nephropathy.

Cochrane Database of Systematic Reviews, 2015
M. Vecchio, B. Bonerba, S. Palmer, J. Craig, M. Ruospo, J. Samuels, D. Molony, F. Schena, G. Strippoli   +8 more
semanticscholar   +1 more source

Comparison of cyclophosphamide, cytarabine, and etoposide as immunosuppressive agents before allogeneic bone marrow transplantation [PDF]

, 1988
W. Gaßmann, L. Uharek, H-U. Wottge, N Schmitz, H. Löffler, W Mueller-Ruchholtz   +5 more
openalex   +1 more source

Therapeutic Reprogramming of Glioblastoma Phenotypic States Using Multifunctional Heparin Nanoparticles

Advanced Science, EarlyView.
This study presents heparin‐derived nanoparticles (HP‐NPs) as a novel precision medicine platform that combines therapeutic and delivery functions. HP‐NPs target drug‐resistant glioblastoma stem cells, reprogramming them into a drug‐sensitive phenotype and significantly reducing tumor progression.
Vadim Le Joncour, Austin D. Evans, Camilla Karoliina Bergström, Vignesh Kumar Rangasami, Sumanta Samanta, Nithiyanandan Krishnan, Yuji Teramura, Bo Nilsson, Patricia Hedenqvist, Elin Manell, Jons Hilborn, Marianne‐Jensen Waern, Oommen P. Varghese, Pirjo Laakkonen, Oommen P. Oommen   +14 more
wiley   +1 more source

Immunosuppressive agents in the treatment of IgA nephropathy: A meta-analysis of clinical randomized controlled literature

, 2020
Xuezhong Gong, Zhaolong Wu, Junli Zheng
openalex   +1 more source

Refractory Status Epilepticus and Therapeutic Uncertainties: a Comprehensive Review on Targeting Neuroinflammation and Rationale for Developing a Platform Trial

Advanced Science, EarlyView.
Refractory status epilepticus (RSE) is a life‐threatening neurological emergency with high rates of death and long‐term disability, but treatments for it are often based on limited evidence. RSE is now understood to involve neuroinflammation, which has led to the exploration of anti‐inflammatory and immunomodulatory agents like Tocilizumab. Traditional
Shanika Samarasekera, Suneesh Thilak, Asha Patel, Prashant Nasa, Zubair Ahmed, Lorraine Jacques, William J. Scotton, Cyril Chacko, Randeep Mullhi, Ruoling Chen, Vikram Patil, Suresh Renukappa, Tonny Veenith   +12 more
wiley   +1 more source

Management of tuberculosis risk, screening and preventive therapy in patients with chronic autoimmune arthritis undergoing biotechnological and targeted immunosuppressive agents. [PDF]

Front Immunol
Picchianti-Diamanti A, Aiello A, De Lorenzo C, Migliori GB, Goletti D.   +4 more
europepmc   +1 more source

Effect of Systemic Lupus Erythematosus and Immunosuppressive Agents on COVID-19 Vaccination Antibody Response. [PDF]

Arthritis Care Res (Hoboken), 2023
Petri M, Joyce D, Haag K, Fava A, Goldman DW, Zhong D, Xiao S, Milstone A, Magder LS.   +8 more
europepmc   +1 more source

CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: Potential role for CB2-selective ligands as immunosuppressive agents

, 2006
Catherine Lombard, Prakash Nagarkatti, Prakash Nagarkatti   +2 more
openalex   +1 more source